MedTrace Logo

Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C

NCT02639585 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-12-28

No results posted yet for this study

Summary

We perform this study to identity efficacy and safety of Daclatasvir and Asunaprevir in real practice.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Daclinza and Sunvepra

direct acting antiviral agent against to hepatitis C virus

Sponsors & Collaborators

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Won Lim, M.S. · Pusan National University Hospital

  • Young Mi Hong, M.S. · Pusan National University Yangsan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-02-28
Completion
2017-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02639585 on ClinicalTrials.gov